Professor of Haematology & lymphoma Consultant , University of Nottingham & Nottingham University Hospitals NHS Trust (no med advice)
United Kingdom
Joined July 2019
- Tweets717
- Following561
- Followers1.5K
- Likes1.5K
Chris Fox retweeted
The #NonHodgkinLymphoma Audit helps improve outcomes by identifying variation in care and highlighting opportunities for improvement across England and Wales.
Patient and Public Involvement and Engagement is such an important part of the audit’s work.
Chris Fox retweeted
Last year we shared the extremely sad news of Lelia Duley's passing. Lelia, an Associate of CLL Support, was passionate about the patient voice being heard and she helped in so many ways to promote awareness of CLL and champion meanigful patient involvement in CLL research.
Chris Fox retweeted
#Lymphoma is the UK’s most common blood cancer. As we come to the end of Blood Cancer Awareness Month, let's keep talking about the symptoms. Please share this post so that more people know the common symptoms to look out for.
Find out more 👉 lymphoma-action.org.uk/Sympt…
ALT 'Know the common symptoms of lymphoma' is written at the top of the page. Next to it is the Lymphoma Action's Let's talk lymphoma logo. Underneath are animations with 'Swollen lymph nodes, Fatigue without reason, Unexplained weight loss, More infections than normal, Drenching night sweats, Itching, Fever, Abdominal swelling, Chest pain, Difficulty swallowing.' written below. Next to it 'Speak to your GP if you are concerned about any of these symptoms' is written.
Chris Fox retweeted
"Thank you to everyone at Cure Leukaemia for embracing the Tour de 4 in the way that you have, and I've been blown away by your support!" Sir Chris Hoy
Earlier this month we were proud to be a partner of Sir Chris Hoy's Tour de 4 and the #CLFamily certainly came out in force to show their support!
We sat down with Sir Chris in Glasgow on the impact of your support, all things Tour de 4 and the benefit of exercise during treatment.
youtu.be/sVePHfWEhtQ?si=GPj4…
Thank you to all those who rode with us in Glasgow, or took part in one of our Tour de 4 Regional Rides in the South, Midlands and the North throughout #ChildhoodCancerAwarenessMonth - you have made a huge difference!
Chris Fox retweeted
Did you know? We fund research nurses across the UK.
🏥 Without research nurses, clinical trials simply wouldn't happen. They are the glue that holds trials together.
🎙️ We’ve had the privilege of welcoming some of our incredible nurses onto our podcast, where they share their experiences and shine a light on the amazing work they do every day.
🎧Listen today at cureleukaemia.co.uk/lets-tal…
Chris Fox retweeted
So much happening in the treatment of DLBCL. New approvals and so many new trials that we are awaiting results for. Thanks so much for @AndyD1036, @ProfChrisPFox and @CathyBu35 for expertly updating us.
Thank you for joining #LymphomaManagement Week 1! Together we covered High-grade non-Hodgkin #Lymphoma: diagnostics & #DLBCL.
You can still book to join the rest of the course & access a recording of tonight's presentation: lymphoma-action.org.uk/Lymph…
@graham74GC @tobyeyre82 #LymSM
ALT Photo of a sign that reads: Thank you! with Lymphoma Action's logo in the corner. There are 7 hands pointing to the sign.
Chris Fox retweeted
“I knew I was going to survive.”
At just 18 years old, Dr. Tom Hunt was diagnosed with Acute Lymphoblastic Leukaemia (ALL). Here's how his positive mental attitude helped him through one of the toughest periods of his life.
🎧 Full episode now live on Spotify, Amazon Podcasts, and YouTube.
Chris Fox retweeted
September is almost here, which means Blood Cancer and Childhood Cancer Awareness Month is just around the corner!
Before we dive into what’s next, we want to say a massive THANK YOU to our incredible #CLFamily. Over the last 12 months, your passion and generosity have helped fund clinical progress and make an impact across the globe 🌍 ❤️
Throughout September, we’ll be highlighting those at the heart of our mission and how you can continue to bring us closer to a cure.
PLUS...we’ll be giving you the chance to win some incredible prizes with our Blood Cancer Awareness Month Prize Draw...🇿🇦 👀
Keep your eyes glued to our page next week and hit the notification bell 🔔 so you don’t miss the launch!
Chris Fox retweeted
British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/…
Chris Fox retweeted
Great opportunity for clinicians to do a PhD with the CRUK City of London Clinical Training Programme. I have a project with Prof Alan Ramsay at Kings investigating stromal metabolic vulnerabilities regulating immune infiltration in lymphoma - please contact me if interested.
Chris Fox retweeted
We are incredibly proud to have been a charity partner of the recent Clays for a Cause, supporting Sir Chris Hoy's Tour de 4 which is just a few months away!
It was an honour for us to attend such an inspiring day and stand alongside everyone dedicated to making a real difference. A massive thank you to Christian Horner and the entire @velocityexperience team for putting together a phenomenal event
The incredible amount of support raised will go a long way in supporting those affected by blood cancer - together, we are driving forward the fight against blood cancer and helping patients access life-saving treatments.
Thank you to everyone who attended, donated, and showed their support!
Congrats!
Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated CLL or SLL (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial - The Lancet thelancet.com/journals/lance…
And what a fantastic patron, champion and role-model the ever-modest Geoff has been! 👏🏾 👏🏾
Today marks 23 years since our patron, Geoff Thomas MBE, was diagnosed with leukaemia.
Instead of letting his diagnosis define him, Geoff turned it into a mission to give hope to others. Through his unwavering dedication, Geoff has helped us support more blood cancer patients around the world, giving families the most precious gift of all: time.
Thank you for everything, Geoff. ❤️
Find out more about Geoff's incredible impact - cureleukaemia.co.uk/news/geo…
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Jun 29, 2026 news.abbvie.com/2026-06-29-A…
Chris Fox retweeted
Have you read our CL brochure yet? 👀
Explore everything about Cure Leukaemia and the impact of our work – all in one place.
Find out more about CL 👉 cureleukaemia.co.uk/app/uplo…
Chris Fox retweeted
CONGRESS | #EHA2026 | PRESENTATION
Christopher Fox presents results from the phase III EPCORE DLBCL-1 trial of epcoritamab vs investigator’s choice CIT in patients with R/R LBCL (n = 483).
Epcoritamab improved IRC-assessed PFS vs CIT (median PFS, 3.5 vs 3.0 months; HR, 0.74; 95% CI, 0.60–0.92; p = 0.0059), with 24-month PFS rates of 30% with epcoritamab vs 13% with CIT. OS was not significantly different and was confounded by COVID-19 mortality and greater use of effective subsequent therapies in the CIT arm; unadjusted median OS was 11.3 months with epcoritamab vs 10.3 months with CIT (HR, 0.96; 95% CI, 0.77–1.20; p = 0.7285), while post hoc adjusted median OS was 16.7 vs 9.5 months, respectively (HR, 0.76; 95% CI, 0.59–0.99). CR rates were 38% with epcoritamab vs 26% with CIT (nominal p = 0.0032), median DoCR was NR vs 10.8 months, and median TTNT was 6.6 vs 4.3 months, respectively (HR, 0.62; 95% CI, 0.50–0.78; p < 0.0001). Grade 3–4 TEAEs occurred in 76% of patients receiving epcoritamab vs 79% receiving CIT, serious TEAEs in 69% vs 32%, Grade 3–4 infections in 30% vs 12%, and fatal TEAEs in 17% vs 6%; in the epcoritamab arm, any-grade CRS occurred in 53%.
Follow our live feed for more updates: bit.ly/4akOvNA
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress @ProfChrisPFox @UniofNottingham @nottmhospitals
Chris Fox retweeted
‼️ #EHA2026 simultaneous publication by @mattwilson2287 et al:
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Analysis of 1,923 Patients
Read the full article: bit.ly/4efwgue
